High Court Won’t Consider Obviousness Of Oxycontin Patent Claims

( October 7, 2025, 11:34 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on Oct. 6 rejected a petition for a writ of certiorari from Purdue Pharma LP and related entities, which told the justices that the Federal Circuit U.S. Court of Appeals has created a rigid nexus test when considering evidence of nonobviousness in a dispute over patents controlling Purdue’s OxyContin drug....